| Logo | Name | Σ | Employees | ||
|---|---|---|---|---|---|
 |  2CFinance [Automatic translation follows] Independent financial consulting firm, specializing in Transaction Services and DAF Part Time Our mission: “Advise investors and managers to diagnose and improve the quality and performance of corporate financial departments”. • Consulting company, based in Paris 9th, Aix-en-Provence and Nantes. • Two professions: delegated operational financial management and financial consulting. • A team of 50 employees. • More than 500 missions carried out in Small and MidCap companies, while respecting absolute discretion and confidentiality. • A portfolio of renowned entrepreneurs, executives and investment funds. • Long experience of supporting companies in different key phases of their development … | 44 | 9 | 38 | 96 |
 | 4BIO Capital London-based venture fund investing in advanced therapies 4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious … Type: | 6 | 2 | 4 | 17 |
 | Abingworth Life Science Investing Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022. Investing in … Type: | 5 | 3 | 2 | 42 |
 |  Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule … Type: | 8 | 5 | 4 | 78 |
 | Abzena Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, … Type: | 6 | 0 | 0 | 446 |
 | Académie des technologies [Automatic translation follows] For reasoned progress, chosen shared Founded in 2000, the Academy of Technologies brings together 370 academics, including five Nobel Prize winners, all experts in their respective fields, and from very diverse backgrounds: the world of industrial and academic research, economists, sociologists, architects. , doctors, etc. It analyzes the opportunities and risks linked to new technologies, and is committed to improving the attractiveness of technological professions, particularly among young people and women. The Academy issues proposals and recommendations to public authorities, socio-economic stakeholders and citizens for better exploitation of technologies for the benefit of people, in accordance with … Type: | 64 | 12 | 69 | 85 |
 | Acteurs de La French Care [Automatic translation follows] The grouping of players who support and develop the health ecosystem in France! The grouping of players who support and develop the health ecosystem in France! Type: | 22 | 4 | 19 | 1 |
 | Adjuvant Capital Adjuvant Capital is the leading investment fund focused on public health. Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Type: | 1 | 0 | 1 | 16 |
 | AFI Ventures Europe’s Day-One Impact Launchpad At AFI Ventures, we are committed to backing the most promising seed & pre-seed impact entrepreneurs. From climate action to healthy living, we partner with every visionary that shares the ambition of deep, at-scale impact. We are investing up to 500k€ in 1 to 2 companies every month. AFI Ventures is the seed fund of Alliance for Impact, Europe's day one impact launchpad. impactinvesting, capitalrisque, VC, impact, startup, fonds, seed, financement, entrepreneurship, and socialbusiness Type: | 15 | 11 | 4 | 5 |
 | AlbionVC Backing visionary founders with long-term capital & scale-up expertise. Partners to B2B software & healthcare companies. AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority. Type: | 23 | 5 | 21 | 27 |
 | Algorithmiq We develop advanced quantum algorithms to solve complex problems in life sciences Algorithmiq is a company developing advanced algorithms to solve complex problems in life sciences. Our mission is to revolutionise life sciences by exploiting the potential of quantum computing to solve currently inaccessible problems. We combine our expertise in quantum information, complex systems, and computational physics to develop algorithms that run on near-term quantum devices to discover new drugs and develop new materials Quantum physics, Complex networks, Quantum computing, Quantum simulations, Quantum chemistry, Quantum software, and Computational physics Type: | 7 | 0 | 7 | 37 |
 | Amadeus Capital Partners We invest in people who create transformational technologies and sustainable businesses. Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back more than 180 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology. Pioneering businesses we’ve backed include cyber security vendor ForeScout (NASDAQ:FSCT); Graphcore, innovators in intelligent microprocessors; IVF genetic testing company, Igenomix; the first single-chip Bluetooth solution, CSR (acquired by Qualcomm); IndiaMART, the B2B online marketplace (NSE: INDIAMART) and speech recognition company … Type: | 37 | 9 | 20 | 52 |
 | American Chemical Society Improving all people’s lives through the transforming power of chemistry. The American Chemical Society is a congressionally chartered independent membership organization that represents professionals at all degree levels and in all fields of the chemical sciences. With more than 150,000 members, ACS is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization, ACS is at the forefront of the evolving chemistry enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe. ACS is dynamic and visionary, committed to “Improving all people’s lives through the … Type: | 3 | 2 | 0 | 2,192 |
 | Amolyt Pharma Advancing peptides for the treatment of rare endocrine and related diseases Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, … Tags: FrenchTech2030 Type: | 9 | 8 | 1 | 61 |
 | Andera Partners The Power of And Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our … Type: | 31 | 17 | 18 | 126 |
 | Andreessen Horowitz Software is eating the world Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, fintech and games spaces. a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, … Type: | 69 | 27 | 20 | 659 |
 | Apollo Global Management, Inc. Apollo is a high-growth alternative asset manager. Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three investing strategies: yield, hybrid, and equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a … Type: | 16 | 3 | 6 | 3,874 |
 | ARCH Venture Partners We are contrarian. We are bold. We are imaginative risk takers. Early stage venture firm focused on life science discoveries to prevent, detect and cure disease. Type: | 2 | 2 | 0 | 62 |
 | Artios Taking control of the DNA Damage Response (DDR) Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. … Type: | 7 | 3 | 0 | 113 |
 | Asabys Partners Investing in Life. Investing in Science. Investing in Future. Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in … Type: | 18 | 3 | 15 | 12 |
 | AstronauTx AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease. Type: | 2 | 0 | 1 | 11 |
 | Atlas Venture We build breakthrough biotech companies with remarkable life science entrepreneurs. Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. Biotech and Venture Capital Type: | 5 | 2 | 3 | 132 |
 | AudioTelligence Disruptive hearing technology start-up (CLOSED) Situational hearing loss is a huge and growing problem worldwide, affecting over 80% of people over 40. Often called ‘The Cocktail Party Problem’, this means that sufferers can hear speech clearly in quiet rooms, but in noisy situations they find it hard to follow conversations. AudioTelligence’s aisoTM technology can supercharge hearing enhancement on your device. AisoTM goes a step further than other solutions which simply reduce background noise, by isolating and extracting the speech or sound that the user wants to hear from surrounding noise and unwanted sounds. With aisoTM, users can effectively regain their … Type: | 17 | 0 | 15 | 7 |
 | baby vc Come for a VC bootcamp, stay for the community. First bootcamp for those who aspire to join the venture capital community. A unique program during which a group of aspiring VCs meet those who make venture capital. They reveal to us behind the scenes, the secrets and the future of their profession. Have a look at our job board juste here: [https://airtable.com/shrePuJCHfJbTq17m/tblsaFTVJnUA2JWuY] Are you a venture capital fund or startup looking for a stellar addition to your team? Then add your job offer via this form [https://airtable.com/shrYcgd6zU6VAKlRL] to get access to our fellows and our community 🤓 venture capital, bootcamp, … Type: | 61 | 2 | 59 | 200 |
 | BeBeez Italia [Automatic translation follows] The first publisher specializing in news and services on private investments in venture and debt capital EdiBeez is the publisher of BeBeez.it and CrowdfundingBuzz.it BeBeez is an online newspaper registered with the Court of Milan (Authorization no. 102 of 3 April 2013), born in the spring of 2013 from an idea by Stefania Peveraro (head of service of MF Milano Finanza) and Anna Gervasoni (general director of the Italian Association of Private Equity and Venture Capital, AIFI). Crowdfunding Buzz is a magazine dedicated to collecting news and information relating to all forms of crowdfunding. Born in December … | 35 | 0 | 35 | 9 |
 | Bicycle Therapeutics Bicycle Precision Guided Therapeutics. Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTCTM) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICATM targeting Nectin-4 and agonizing CD137, … Type: | 6 | 2 | 1 | 274 |
 | Bien Commun Advisory [Automatic translation follows] The conviction that, in the “common good”, the greatest good is first and foremost what is common to us. Bien Commun Advisory is a consulting firm in communications strategy, economic information, public affairs and media relations. Founded by Antoine Boulay in 2019, it now has around fifteen employees and operates for large companies, SMEs, start-ups, federations and players in the associative world. Type: | 34 | 1 | 29 | 14 |
 | BioCentury Inc. The leading voice for decision makers throughout the global healthcare ecosystem. BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The … Type: | 10 | 4 | 8 | 77 |
 | BIOKET Bioeconomy Key Enabling Technologies platform Process & Technology innovations for biobased solutions to food, feed, chemicals, biomaterials and bioenergies Trois-Rivières (QC), Canada -- May 23th-25th, 2023 -- Biomass is a wonderful ressource to be transformed into chemicals, biobased materials, food and feed ingredients or energy. Still, adaptation and optimisation of transformation processes and technologies is a real challenge in order to valorise all biomass fraction in a circular approach. In the context of Industry 4.0, the circular economy and the need for an optimal valorization of renewable resources, BIOKET is the only European conference dedicated to bio-based technologies and processes. Innovative Processes, Biotechnology, Green Chemistry, … Type: | 28 | 9 | 22 | 2 |
 | Bioptimus We build foundation models that will transform biology. We use cutting-edge technology to transform multiscale data into actionable representations to fuel breakthrough discoveries. Join us on our mission to build foundation models that transform biology. artificial intelligence, biology, and foundation models Type: | 4 | 2 | 3 | 13 |
 | Biotalys Reinventing food protection We are a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on our ground-breaking technology platform, Biotalys is developing a broad pipeline of effective and safe products with novel modes of action, addressing key crop pests and diseases across the whole value chain, from soil to plate. Biotalys’ unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. We are … Type: | 6 | 3 | 5 | 69 |
 | BIOTECanada Solving for today. Building for tomorrow. BIOTECanada serves as the national voice for Canada’s biotechnology sector. BIOTECanada is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations. Through our national network of partner organisations, we inspire our domestic and international community to recognize the value of biotechnology and to provide solutions to the challenges faced by biotech firms today. Visit us at www.biotech.ca, and discover Canada's Biotechnology and Lifesciences Community … | 6 | 1 | 5 | 25 |
 | BIOTECHFINANCES [Automatic translation follows] 1st weekly specialist information, biotech, medtech, e-health, finance published by Jacques Bernard Taste PRESENTATION The weekly Biotech Finances letter approaches from an economic and financial angle all questions linked to the development of the biotechnology sector and more broadly life sciences. Our target readership is mainly composed of biotechnology companies focused on health and the development of new therapies and new treatments for diseases, pharmaceutical companies (big pharma and other laboratories), investors, business angels, funds investments, venture capital, specialists in the biotech sector, institutional investors, legal advisors, development experts, and service providers and equipment suppliers. Our articles … Type: | 13 | 4 | 3 | 9 |
 | BIOWEG Revolutionizing the Future of Bio-ingredients BIOWEG, founded in 2019 in Germany, is a purpose-driven organization powered by conscious ChemDesign. We match Bio-innovation to business problems. We explore and combine biotechnology, material science, and molecular simulation learning to create advanced sustainable bio-based high-performance ingredients. Our ingredients are 100% animal free, globally scalable, and sustainably produced without harsh chemicals. We work with results-oriented, forward-thinking companies, and consumer brands with global scale in the cosmetics, personal care, nutraceuticals, agricultural coatings, and food/beverage sectors who desire highly differentiated and sustainable science-based ingredient technologies. Material Science, Fermentation , Green Chemistry, Alternative Ingredients, Biobased Materials, Biodegradabe, … Type: | 22 | 3 | 2 | 20 |
 | Bon Vivant Animal-free dairy proteins, for a sustainable future. We are a French biotechnology company developing cutting-edge precision fermentation techniques, dedicated to take part in the environmental transition within the dairy production sector. Our innovative technology enables the production of dairy proteins without the need for animals, significantly reducing the ecological footprint. By providing our clients with cutting-edge, sustainable ingredients, we empower them to create a diverse range of dairy products identical to those you already love, both environmentally conscious and nutritionally rich. Join us on our journey to shaping a future where ethical dairy alternatives are complementary to conventional farming and … Type: | 31 | 10 | 22 | 71 |
 | BRAIN Biotech AG Developing a biobased future is our passion. Industrial biotechnology is our business. BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in … Type: | 3 | 1 | 1 | 186 |
 | BrightHeart Advancing prenatal ultrasound screening with AI At BrightHeart, we believe every single fetal ultrasound screening exam should be performed with the highest level of accuracy, so each mother and baby receive the highest possible quality of care. Type: | 2 | 2 | 1 | 12 |
 | Bruntwood 💡 Creating Thriving Cities: Workspace | Laboratories | Retail | Leisure Workspace | Laboratories | Retail | Leisure We own, let and manage outstanding buildings, workspace, innovation and science facilities through Bruntwood SciTech and Bruntwood Works. Our purpose: creating thriving cities. This purpose fuels our passion for supporting arts and culture, our deep community engagement and our ambitious plans for future growth. It ensures every investment and decision we make benefits our customers, our communities and our colleagues: because when our cities thrive, so do we. Our commitment to creating thriving cities has helped us to grow into a company … | 19 | 1 | 13 | 676 |
 | BT Group We’re one of the world’s leading communications services companies. At BT Group, the solutions we sell are integral to modern life. Our purpose is as simple as it is ambitious: we connect for good. There are no limits to what people can do when they connect. And as technology changes our world, connections are becoming even more important to everyday life. Today, that’s truer than ever. The connections we make are helping solve the world’s biggest challenges such as the global pandemic, climate change and cyber security. Through the power of technology, we’re supporting customers to live, work and play … Type: | 15 | 11 | 2 | 80,389 |
 | Business Insider What you want to know. Follow us on Facebook, Instagram, YouTube, and TikTok. Visit our homepage for the day's top stories. Type: | 135 | 77 | 59 | 5,627 |
 | Calliditas Therapeutics Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients. Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products. Type: | 5 | 2 | 0 | 228 |
 | Calm/Storm Entrepreneurship is a continuous storm Calm/Storm is an exclusive founder network and boutique venture capital firm. We focus on talents, not industries. We believe in lifelong learning & personal growth, empowering entrepreneurs with unique access to successful founders. We are a fund built by founders for founders. Type: | 16 | 4 | 15 | 34 |
 | Cambridge Innovation Capital A leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies. Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. CIC currently manages over £500 million and has invested in 30+ companies. We invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics. IP Commercialisation, Venture Capital, healthcare, … Type: | 13 | 4 | 5 | 32 |
 | Cancer Campus [Automatic translation follows] Cancer Campus is a research and innovation park developing in Villejuif (Val-de-Marne) Cancer Campus is a research and innovation park developing in Villejuif (Val-de-Marne), around Gustave Roussy, the first cancer center in Europe. Its objective is to bring together all the talents (health professionals, researchers, students, businesses) and citizens concerned by the disease to become an international reference site in innovation in health and oncology. In this context, we are developing 3 programs dedicated to promoting entrepreneurship in oncology: - the Oncoentrepreneur program: tailor-made training and support set up for start-up projects in biotech, medtech and e-health. … Type: | 5 | 1 | 3 | 3 |
 | Cardiologs AI Serving Cardiology Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence. Machine Learning, Big Data, MedTech, Cardiology, Artificial Intelligence, ECG analysis, Holter analysis, and SaaS Type: | 14 | 9 | 3 | 88 |
 | Casdin Capital, LLC Life Science Investments Casdin Capital, LLC is a New York-based research investment firm focused on the innovations in molecular medicine currently reshaping Life Sciences and healthcare. Founded in 2011, and with an eye to long-term returns and disruptive technologies, Casdin Capital is an expert working with experts, benefiting from its position at the crossroads of the science and investment communities. As trusted investor-partners in both private and public companies, we collaborate with industry leaders to fuel their visions, adding energy, insight, and experience to our over $2.4 billion under management. As we push into new markets and new developments, we … Type: | 6 | 2 | 0 | 48 |
 | Cathay Capital Cathay Capital, Connecting People to Achieve the Extraodinary About Cathay Capital Group Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now … Type: | 44 | 9 | 33 | 143 |
 |  Catsalyze We improve your enzymes. Catsalyze will revolutionize enzymatic biocatalyze. Our proprietary technology allows us to graft enzymes around a protein ring, which gives them strong advantages such as increased stability, solubility, efficiency but also the possibility of assembling these grafted rings to create perfectly colocalized enzymatic cascades. . So extremely effective. Our challenge? Transform biomass in a gentle and clean way and through accelullar enzymatic catalysis into chemical bricks classically petrosourced and synthesized with pollution. The future of chemistry passes through Catsalyze. Type: | 24 | 4 | 21 | 2 |
 | Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory Type: | 1 | 0 | 0 | 20 |
 | centdegrés Creative Activists Since 1988 We believe in bold creativity. For thirty years, we’ve focused all our energies on helping our clients win their battles, improve their impact, and challenge the status quo. Through design. We hunt down the best conditions for your projects in order to create unique personalised design and make a new kind of impact. Anything that will only achieve a partial result is a waste of time. We live by the certainty that there is no such thing as “hype”, freedom and creativity are crucial aspects of our approach. We have continuously created exceptional experiences, brands, products … | 2 | 2 | 2 | 62 |
 | Chausson Partners We match smart money with great companies Chausson Finance is a leading fundraising advisory firm, providing deal making and equity story advice, as well as devoted support to inspiring founders. We helped shape +250 deals, and raise $1Bn. Our community of clients include leadership teams funded by Accel, Balderton, Alven and other top venture investors. Fundraising, Corporate Finance, Venture Capital, investment banking, equity rounds, M&A, Series A, Series B, and Equity Financing Type: | 18 | 2 | 16 | 17 |
 | Citeline Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. Type: | 12 | 10 | 2 | 420 |
 | CONCILIO Your key to better care. Concilio gives you access to the best in health care. In a world where doctors are becoming super-specialized, it’s not always easy to obtain reliable information and to know exactly who to turn to for your specific medical issue. As the first digital medical concierge service, Concilio aims to democratize access to the best in health care. Wherever you are in the world, our dedicated medical team is there to help you every day with more than 5 000 pathologies. E-santé, Téléconsultation, Recherche de Médecins, Bilan Santé, téléconseil médical, télémédecine, Médecins généralistes, Médecins Spécialistes, Conciergerie … Type: | 16 | 5 | 9 | 40 |
 | CorWave CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology. CorWave is a French company developing innovative cardiac assist devices. CorWave’s wave membrane pump is a breakthrough technology that differs from today’s commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave’s membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up … Tags: FrenchTech120 Type: | 24 | 10 | 22 | 91 |
 | Crédit Mutuel Innovation [Automatic translation follows] Our relationships bring value Crédit Mutuel Innovation is the subsidiary specializing in venture capital investments of Crédit Mutuel Equity (€4 billion in capital managed). It invests in equity tickets of between €1 and €20 million in innovative deeptech, digital and life sciences companies. Crédit Mutuel Innovation allows entrepreneurs to develop their growth potential by connecting them to companies in its ecosystems. Because it takes more than 5 years to create a world leader, Crédit Mutuel Innovation invests its own capital sustainably and builds long-term relationships with the entrepreneurs it supports. Type: | 44 | 22 | 31 | 19 |
 | Crescendo Biologics Limited Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical … Type: | 4 | 2 | 3 | 63 |
 | Cure51 From Cancer Survivors to new drugs The first worldwide clinical and molecular database of exceptional survivors leading the path to new therapies against cancer. Type: | 2 | 1 | 0 | 15 |
 | Cyber Valley Europe’s largest AI research consortium Cyber Valley is Europe’s largest and leading research consortium in the field of artificial intelligence (AI) and modern robotics. Cyber Valley has a mission and a public mandate to advocate for entrepreneurship, research, development, application, and acceptance of technologies and methods in the field of intelligent systems. The company envisions a future where the full potential of intelligent systems is leveraged for the greater good of the world. The Cyber Valley Community connects partners from science, industry, and society, along with AI researchers and entrepreneurs. The Cyber Valley GmbH is funded by the state of … Type: | 9 | 1 | 6 | 20 |
 | datacraft [Automatic translation follows] The data scientists club datacraft allows an exchange of best practices between data experts. It is a unique Club model, inspired by companionship, and designed to allow data scientists/data engineers to train among peers and enable companies to accelerate their AI/data projects. Access to the Club is through an annual membership. Type: | 48 | 8 | 35 | 17 |
 | Dechert LLP Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors. © 2024 Dechert LLP. All rights reserved. This information should not be considered as legal opinions on specific facts or as … Type: | 10 | 6 | 5 | 2,229 |
 | deepc Increasing diagnostic quality through the collaboration of medical professionals and AI. deepc is a pioneering company in the realm of Radiology AI, poised to democratize access to health at scale. At the heart of our mission is ourproduct deepcOS®, an unrivaled cloud-native Radiology AI platform. With a vendor-agnostic approach, deepcOS® boasts an expansive repository of cutting-edge AI applications. This groundbreaking platform empowers radiologists to seamlessly include AI insights into their clinical workflows, ushering in a new era of patient care excellence and elevated diagnostic precision. Visit our website now or simply email us at contact@deepc.ai Digital Health, Deep Learning, Machine … Type: | 1 | 1 | 0 | 74 |
 | Dieter von Holtzbrinck Ventures DvH Ventures | Investing early in Europe's most passionate founders. Dieter von Holtzbrinck Ventures (DvH Ventures) is one of Europe's leading early stage investors. As an entrepreneurial venture capitalist, DvH Ventures invests in emerging technology companies and builds successful investment clusters in areas such as Digital Health, Education, DeepTech or Climate Tech/ESG. Founded in 2014, partners Duc Quyen Tran, Peter Richarz and Fabian von Trotha manage several venture capital funds from their Cologne office. In addition to financial investments, DvH Ventures supports its portfolio companies with management expertise, in-depth industry knowledge and an international investor network. An exclusive media-for-equity programme … Type: | 25 | 6 | 18 | 10 |
 | DNA Script Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine. Synthetic Biology, Biotechnology, DNA synthesis, Sciences, Research, Development, Start-up, and Technology Tags: FrenchTech120 FrenchTech2030 Type: | 31 | 12 | 22 | 210 |
 | Drug Discovery World The Global Business Review of Drug Discovery and Development Welcome to our LinkedIn page. This is where we will share original content from the DDW team and industry experts, as well as daily news and other company updates. Published for over 20 years, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry … Type: | 19 | 2 | 17 | 9 |
 | Ecofi [Automatic translation follows] Active for the future Management that influences tomorrow In 1972 our first Sicav was born, which has since become Epargne Ethique Flexible. 1st sharing fund in Europe created in 1983, launch of our solidarity fund in 2002, range of 100% SRI* funds in 2019, first French management company to adopt the status of mission-driven company in 2020... Ecofi works to daily to combine financial performance and respect for People and the Planet. This commitment has only grown over the years. Today, Ecofi is more than ever committed to the long term, combining control, involvement and sincerity to … Type: | 38 | 7 | 22 | 95 |
 | Eight Roads We back and partner with game-changing technology and healthcare companies in China, Europe, India, Japan and the US. Eight Roads Ventures is a global venture capital firm backed by Fidelity that helps entrepreneurs scale. We back and partner with game-changing technology and healthcare companies. With a presence in China, Europe, India and Japan, our global platform has 50+ years of venture investing experience, $11 Bn in AUM, over 300 portfolio companies and 60+ IPOs. Healthcare, Biosciences & Life Sciences, Consumer Technology, Internet & e-Commerce, FinTech & FinServ, Telecommunications, Food & Agriculture, Education and Skills Development, Enterprise Tech, Pharmaceuticals, Edu Tech, … Type: | 31 | 6 | 18 | 206 |
 | ELICIT PLANT The only efficient Bio-Intrant to fight Water Stress ELICIT PLANT is an AGtech company and a pioneer in the stimulation of field-grown plants through the use of phytosterols. By reducing plant water stress, our patented technology increases yield in situation of lack of water. Elicit Plant develops and provides new effective prevention products against the stress suffered by plants grown by the intake of exogenous phytosterols in the field. Elicit Plant offers a novel solution for reducing water consumption for the cultivation of targeted plants and helps to fight against water stress. Elicit Plants develops a methodology to collect soil, … Tags: FrenchTech2030 Type: | 18 | 10 | 11 | 76 |
 | Eli Lilly and Company For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. General Information and Guidelines: Eli Lilly and Company strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse. When you engage with Lilly on LinkedIn (and any other of Lilly’s social … Type: | 60 | 16 | 33 | 42,831 |
 | Endpoints News The biopharma world is here Endpoints is the biopharma world's leading source for breaking news, smart analysis and exclusive access. We cover the intersection of science, money and power in the world's most innovative industry, and are a part of the Financial Times' FT Specialist group. Biotechnology, News, Drug Development, and Pharmaceuticals Type: | 20 | 3 | 19 | 62 |
 | Enersens Enersens produces the best thermal barriers and additives to improve safety, energy efficiency and flame protection Enersens is a leading innovative company specializing in silica aerogel products. We develop and market high performance aerogel-based insulation materials. We aim to become the leader in these high performance materials to enable our customers and partners to achieve their own goals around global trends in energy efficiency, sustainability, electric mobility and clean energy. Our Skogar® products solve the thermal runaway problems of batteries for any type of electric vehicle or electric mobility. Their performance and finesse also make it possible to solve many … Type: | 23 | 5 | 21 | 7 |
 | EnginZyme Developing technologies to meet the sustainability goals of the future Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the … Type: | 2 | 0 | 2 | 59 |
 | ENYO Pharma Developing therapeutics for diseases with impaired kidney function ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor. Type: | 8 | 3 | 5 | 31 |
 | EQT Group EQT is a purpose-driven global investment organization EQT is a purpose-driven global investment organization with close to three decades of consistent investment performance across multiple geographies, sectors, and strategies. Type: | 20 | 11 | 9 | 1,291 |
 | EryPharm EryPharm is a biotech start-up company dedicated to the development and the operation of a large-scale process for the production of Red Blood Cells from stem cells. The technology has been developed by Dr. Luc Douay and his team at the Paris Sorbonne university. You can contact EryPharm through our website: http://erypharm.com/contact.html Or you can contact Loïc Tron directly: www.linkedin.com/in/loictron Type: | 9 | 1 | 8 | 3 |
 | Esquire magazine The most stylish and substantial men’s magazine. A one-stop shop for lifestyle advice – cars, culture, grooming, gadgets, food, fashion and more – and a showcase for brilliant journalism and photography. Esquire is intelligent, irreverent and unapologetically masculine. Type: | 10 | 8 | 10 | 286 |
 | EuropaBio - the European Association for Bioindustries Innovative biotechnology, benefiting people and planet. EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. Type: | 21 | 6 | 18 | 29 |
 | Evaluate Ltd Evaluate provides trusted commercial intelligence and predictive analytics to the pharmaceutical industry Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action: Evaluate Omnium - provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential. EvaluatePharma - the trusted global view of the … Type: | 7 | 1 | 5 | 200 |
 | Evonik Leading in specialty chemicals and beyond to make the world a better place. Evonik is one of the world’s leading specialty chemicals companies. While we don’t produce electric cars, aircraft, medications or 3D printers, Evonik is part and parcel of these and many other end products. That’s because we contribute the small things that make a big difference. We make electric car batteries perform better, aircraft greener, medications more effective and 3D printers more efficient. In short: We think beyond the bounds of chemistry to make the world a better place. Today and tomorrow. We are an international group with … Type: | 11 | 4 | 5 | 13,487 |
 | Fast Company Inspiring the future of business. Fast Company is the world’s leading business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, creativity, and design. Written for and about the most progressive business leaders, Fast Company inspires readers to think expansively, lead with purpose, embrace change, and shape the future of business. social media Type: | 84 | 60 | 21 | 2,945 |
 | Federal Ministry for Economic Affairs and Climate Action The major trends of the 21st century, notably globalisation, digitisation, demographic change, recent developments within the EU, and climate change all represent major challenges for German business to tackle. If we are to successfully address these issues, we need to develop our social market economy into a social-ecological market economy. This is the over-arching task for the Federal Ministry for Economic Affairs and Climate Action. Wirtschaft, Digitalisierung, Handelspolitik, Mittelstandspolitik, Energiewende, Europa, Wirtschaftliche Entwicklung, Industriepolitik, Luft- und Raumfahrt, Erneuerbare Energien, Außenwirtschaftsförderung, Existenzgründung, Tourismuspolitik, Energieeffizienz, Maritime Wirtschaft, Netzausbau, and Industrie 4.0 Type: | 73 | 30 | 16 | 930 |
 | Forbion Impacting the future of medicine Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. … Type: | 6 | 4 | 3 | 60 |
 | Form the Future CIC We help young people find their route through education into employment, and provide employers access to future talent We connect young people to a world of career possibilities, inspire them to dream big and empower them to fulfil their potential. We want to equip young people with the experience and skills they will need to succeed in their career of choice, and enable businesses to recruit skilled workers locally. We bridge the gap between these two worlds and help them work together and achieve more. We deliver the skills service for the Greater Cambridge Partnership, linking schools and businesses to … Type: | 10 | 0 | 8 | 37 |
 | Founders Future Founded by entrepreneurs for entrepreneurs, we invest financial and human capital in tech and digital startups. Founded by the serial European tech entrepreneur, Marc Ménasé, Founders Future is a venture studio, providing creativity, network, support and productive capital. We've built a investment platform dedicated to entrepreneurs and managed by entrepreneurs, bringing high value and an ambitious mindset. We aim to partner with outstanding personalities, to align stakeholder’s interest and to foster operational partnerships. Our mission is to become a sparring-partner and continuously try to impact the business on the product, go-to-market, business development and talent acquisition. We've hired top-notch operating … Type: | 64 | 26 | 50 | 19 |
 | F-Prime Capital We create and invest in healthcare and technology companies that impact lives all over the world. Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx. Today our funds … Type: | 7 | 2 | 6 | 81 |
 | France Deeptech [Automatic translation follows] When science undertakes The community that brings together deeptech players for an entrepreneurial, collective and scientific response to our contemporary challenges Type: | 44 | 11 | 39 | 6 |
 | Frst We are the first believers Frst is a Day One venture firm focused on supporting a new generation of French entrepreneurs with global ambitions. €200m+ AUMA invested in 50+ companies to date. Full portfolio on frst.vc Type: | 6 | 5 | 0 | 6 |
 | GAE Conseil [Automatic translation follows] Expert in the prevention of addictive practices in professional environments: advice, awareness, training, etc. G.A.E Conseil, the leading player in the prevention of addictive practices at work. Founded in 2014, GAE Conseil is an independent consulting firm specializing in the prevention of addictive practices in professional environments (psychoactive products and behavioral addictions). Around the partners of the firm and the heads of the different centers of expertise (Audit and Consulting Center, Training Center, Assistance Center for employees in difficulty), the GAE Conseil teams support private and public companies of all sizes and of all types. sectors of … Type: | 44 | 0 | 43 | 36 |
 | GENFIT Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, … Type: | 7 | 3 | 5 | 172 |
 | GFBiochemicals GFBiochemicals is on a mission to create a more sustainable future and transform the chemicals industry GFBiochemicals is a biochemical company that specializes in the research, development, production and business development of bio-based and renewable chemicals. We provide high-quality, bio-based chemicals to businesses across the world. Our focus is green chemistry – a sustainable alternative to traditional oil-based chemistry. Our technology is proprietary and has been developed in-house over many years. GFBiochemicals is headquartered in Paris, France and has subsidiaries in Geleen, the Netherlands and Minneapolis, USA. GFBiochemicals acquired Segetis, in 2016, as part of our growth strategy to integrate … Type: | 5 | 2 | 3 | 33 |
 | Gilde Healthcare Specialized healthcare investor in both Healthcare Venture & Growth as well as Healthcare Private Equity, managing €2.5B Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde Healthcare's lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare's venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are … Type: | 5 | 3 | 2 | 62 |
 | GIMLI Leverage Real World Evidence in oncology Gimli empowers medical professionals to structure medical data. We extract and structure data directly from the EMR to streamline RWD, allowing the generation of strong RWE. Ask us for a demo! Gimli is a Startup working with university hospitals, pharmaceutical companies, data analytics providers, and startups. Type: | 21 | 2 | 11 | 7 |
 | GOURMEY 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. [join.gourmey.com] GOURMEY is France's pioneering cultivated meat company. 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. > Join.gourmey.com Type: | 33 | 9 | 27 | 97 |
 | Gradient Denervation Technologies Transforming the treatment of pulmonary hypertension A solution for patients suffering from heart failure with pulmonary hypertension. Type: | 1 | 1 | 0 | 13 |
 | Groupe Stratos Groupe STRATOS is an entrepreneurs community providing companies with custom-made solutions. Groupe STRATOS is an entrepreneurs community providing companies with custom-made solutions. Our community is composed of entrepreneurs with expertise on a specific topic and each single member is/was an entrepreneur. Groupe STRATOS was founded in 2020 with the merger of 2 other companies created 10 & 20 years ago. About our advisory activiy : - Fund raisings through our network of +1 000 investors (France & International) - Mergers & Acquisitions - Financial audits (M&A, valuation of companies, due diligence...) - Financial analysis - Strategy & business development - … Type: | 54 | 2 | 54 | 8 |
 | GTM Forum Navigate the Go to market landscape GTM Forum is your premier analyst partner in go-to-market strategies, serving leading B2B companies worldwide. Our expertise across multiple sectors uniquely positions us to address your complex challenges effectively. With our broad knowledge base and global reach, we are dedicated to making a significant impact on both our clients and the community. We create a collaborative environment that boosts your team's capabilities and leadership, providing tailored support to tackle fundamental issues and offer practical solutions. Our mission is to empower your organization to drive and maintain progress in your strategic endeavors. Specializing in mid-market … Type: | 33 | 0 | 33 | 23 |
 | GV (Google Ventures) Launched as Google Ventures in 2009, GV supports innovative founders moving the world forward. GV supports innovative founders moving the world forward. We invest across the life sciences, consumer, enterprise, crypto, climate, and frontier technology sectors. With Alphabet as a sole limited partner, GV operates on long time horizons and deals in decades, not rounds. Our operating partners help startups at the earliest stages of company-building across design, equity, diversity & inclusion, talent, and engineering. We also help startups interface with Google, providing unique access to the world’s best technology and talent. Launched as Google Ventures in 2009, GV has … Type: | 12 | 4 | 6 | 240 |
 | Handelsblatt [Automatic translation follows] Germany's business and financial newspaper / Substance decides. The Handelsblatt is the largest business and financial newspaper in German. Around 200 editors and correspondents worldwide represent well-founded and independent quality journalism that researches and analyzes exclusively and up-to-date national and global topics and events. With around 40 correspondents abroad, the Handelsblatt is present in all economic centers in the world. News, economy, stock market, economic policy, finance, and money Type: | 137 | 81 | 39 | 488 |
 | Harlay Avocats #tech#startups#corporate#IP/IT#social#employment#tax Harlay Avocats (anciennement Kahn & Associés) est un cabinet d’avocats indépendant qui occupe depuis plus de vingt ans une place privilégiée dans le domaine du conseil aux entreprises de croissance et aux investisseurs dans les secteurs des technologies, de l’Internet, de l’e-commerce, des télécommunications, des sciences de la vie et des énergies renouvelables. La très bonne connaissance de ces secteurs d’activité permet au Cabinet d’être régulièrement sélectionné par les acteurs clés de ces domaines pour les assister lors de leurs opérations en France et à l’international. Le Cabinet conseille également les entreprises d’industries plus traditionnelles : presse et media, … | 5 | 0 | 4 | 37 |
 | HarperCollins Publishers Publishing great authors since 1817. HarperCollins Publishers is the second-largest consumer book publisher in the world. Headquartered in New York, HarperCollins has publishing operations in 17 countries. With two hundred years of history and more than 120 branded imprints around the world, HarperCollins publishes approximately 10,000 new books every year in 16 languages, and has a print and digital catalog of more than 200,000 titles. Writing across dozens of genres, HarperCollins authors include winners of the Nobel Prize, the Pulitzer Prize, the National Book Award, the Newbery and Caldecott Medals, and the Man Booker Prize. HarperCollins is a subsidiary of … Type: | 15 | 4 | 11 | 4,129 |
 | Headline We help founders win, bigger Headline is a Venture Capital firm actively on the ground in 7 cities around the world. We invest across geographies, leading rounds at every stage. Once we commit to a team, we go to the ends of the earth to make their success global. Our Early Stage Funds are based in the US, Europe, Asia, and Brazil, and invest locally. Our San Francisco-based Growth Fund invests globally from Series B and beyond, working in collaboration with our Early Stage Teams. The sizes and locations of these funds make it possible for us to see local … Type: | 18 | 11 | 7 | 179 |
Startup